139 results match your criteria Management of the N3 Neck


Survival of nasopharyngeal cancer in national referral hospital of Indonesia: A study on radiotherapy patients.

Oral Oncol 2020 07 16;106:104707. Epub 2020 Apr 16.

Department of Ear, Nose Throat-Head and Neck Surgery, Faculty of Medicine Universitas Indonesia-Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia.

Introduction: Nasopharyngeal cancer in Indonesia has a poor survival rate and there is only few studies regarding nasopharyngeal cancer in Indonesia. Therefore, this study was made to present Indonesian nasopharyngeal cancer data with special focus on survival of nasopharyngeal cancer profile that receives radiation therapy.

Methods: This was a retrospective study conducted in the Department of Radiation Oncology, Dr. Read More

View Article and Full-Text PDF

Current management of stage IV nasopharyngeal carcinoma without distant metastasis.

Cancer Treat Rev 2020 Apr 21;85:101995. Epub 2020 Feb 21.

International Head and Neck Scientific Group, Padua, Italy.

Up to one in four patients with nasopharyngeal carcinoma present with non-metastatic stage IV disease (i.e. T4 or N3). Read More

View Article and Full-Text PDF

Survival outcomes for head and neck cancer patients with N3 cervical nodal metastases.

Clin Otolaryngol 2020 05 20;45(3):342-349. Epub 2020 Feb 20.

Head and Neck Unit, Imperial College Healthcare NHS Trust, London, UK.

Background: Management of metastatic N3 nodal disease from primary head and neck squamous cell carcinoma (HNSCC) is controversial. Recently, there has been a move to observation of the neck for those who achieve complete response (CR) after chemoradiotherapy (CRT). We sought to determine survival outcomes for N3 nodal disease, particularly for patients with human papilloma virus (HPV)-positive HNSCC. Read More

View Article and Full-Text PDF

Transoral robotic surgery in the management of head and neck squamous cell cancer with unknown primary.

Acta Otolaryngol 2020 Jan 18;140(1):85-88. Epub 2019 Nov 18.

Department of ORL, Head and Neck Surgery, Skåne University Hospital, Lund, Sweden.

Transoral robotic surgery (TORS) assisted base of the tongue (BOT) resection has been suggested as part of the work-up for head and neck squamous cell cancer with unknown primary (HNSCC-CUP). Success rates vary with regard to identification of primary BOT lesions, and cases with likely such lesions appear to be included in previous reports. To analyse the possible benefits of a superficial TORS-assisted BOT resection in thoroughly investigated HNSCC-CUP. Read More

View Article and Full-Text PDF
January 2020

Trimodality therapy for HPV-positive oropharyngeal cancer: A population-based study: Trimodality therapy for HPV+ OPC.

Oral Oncol 2019 11 16;98:28-34. Epub 2019 Sep 16.

Harvard Radiation Oncology Program, Massachusetts General Hospital, Boston, MA, United States.

Background: Although HPV status is a well-established prognostic factor in oropharyngeal squamous cell carcinoma (OPSCC), approximately 20% of HPV-positive patients die from their disease. We therefore sought to ascertain whether there is a benefit to trimodality therapy with surgery among patients with locally advanced (LA) disease receiving chemoradiation.

Methods: The SEER Head and Neck with HPV Status Database identified adult patients with non-metastatic OPSCC between 2013 and 2014 with known HPV status who received chemoradiation as part of definitive treatment. Read More

View Article and Full-Text PDF
November 2019

Improved Overall Survival With Comprehensive Local Consolidative Therapy in Synchronous Oligometastatic Non-Small-Cell Lung Cancer.

Clin Lung Cancer 2020 01 1;21(1):37-46.e7. Epub 2019 Aug 1.

Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address:

Background: Local consolidative therapy (LCT) to optimize disease control is an evolving management paradigm in non-small-cell lung cancer (NSCLC) patients who present with a limited metastatic disease burden. We hypothesized that LCT to all sites of disease would be associated with improved overall survival (OS) among patients with synchronous oligometastatic NSCLC.

Patients And Methods: Patients presenting to a single institution (2000-2017) with stage IV NSCLC and ≤ 3 synchronous metastases were identified. Read More

View Article and Full-Text PDF
January 2020

Staging and Response Evaluation to Neo-Adjuvant Chemoradiation in Esophageal Cancers Using 18FDG PET/ CT with Standardized Protocol.

Asian Pac J Cancer Prev 2019 07 1;20(7):2003-2008. Epub 2019 Jul 1.

Dow Medical College, Dow University of Health Sciences (DUHS), Karachi, Pakistan.

Background: Precise staging of esophageal cancer (EC) is important for selection of optimal treatment option and prognostication. Aim of this study was to assess the role of 18FDG PET/CT in staging and response evaluation to neoadjuvant chemoradiation (nCR) in EC patients using standardized imaging protocol. Material and methods: This prospective study was conducted at PET/CT Section of Department of Radiology, Aga Khan University Hospital Karachi, Pakistan from July 2017 till February 2018. Read More

View Article and Full-Text PDF

Comparing surgical and nonsurgical larynx-preserving treatments with total laryngectomy for locally advanced laryngeal cancer.

Cancer 2019 Oct 17;125(19):3367-3377. Epub 2019 Jun 17.

Department of Radiation Oncology, Boston Medical Center, Boston University School of Medicine, Boston, Massachusetts.

Background: The declining 5-year overall survival (OS) of patients with laryngeal cancer has been associated with increased nonsurgical management of stage III/IV disease. To further assess this hypothesis, the authors evaluated recent OS trends and patterns of use between larynx-preserving approaches with chemoradiation (CRT) or partial laryngectomy (PL) and total laryngectomy (TL) stratified by tumor and nodal burden.

Methods: The National Cancer Data Base was used to identify 8703 patients with stage III/IV (excluding T1 tumors) laryngeal squamous cell carcinoma treated between 2003 and 2011 with CRT or upfront PL or TL with or without adjuvant therapy. Read More

View Article and Full-Text PDF
October 2019

Neck management in head and neck squamous cell carcinomas: where do we stand?

Med Oncol 2019 Mar 27;36(5):40. Epub 2019 Mar 27.

Radiation Oncology Department, François Baclesse Center/ARCHADE, Normandy University, 3 Avenue du Général Harris, 14000, Caen, France.

Head and neck squamous-cell carcinomas (HNSCCs) have a significant lymph node tropism. This varies considerably depending on the primary tumor site and the Human Papillomavirus (HPV) status of the disease. The best therapeutic option, between up-front lymph node dissection and chemoradiotherapy (CRT) +/- followed by lymph node dissection in case of persistent lymphadenopathy or regional relapse, remains unclear. Read More

View Article and Full-Text PDF

Prognostic factors in patients with soft palate squamous cell carcinoma.

Head Neck 2019 05 12;41(5):1441-1449. Epub 2019 Jan 12.

Radiation Oncology Department, Gustave Roussy Cancer Campus, Paris, France.

Background: To define the prognostic factors associated with outcome in patients with soft palate squamous cell carcinoma (SCC).

Methods: Previously untreated patients with soft palate and uvula SCC treated in our institution between 1997 and 2012 were collected. The prognostic value of clinical, hematological, and treatment characteristics was examined. Read More

View Article and Full-Text PDF

Smoking and papillomavirus DNA in patients with p16-positive N3 oropharyngeal squamous cell carcinoma.

Head Neck 2019 04 15;41(4):1039-1045. Epub 2018 Dec 15.

Department of Head and Neck Oncology, Gustave Roussy Institute, Université Paris-Saclay, Villejuif, France.

Background: We investigated the survival of patients with a p16-positive N3 oropharyngeal squamous cell carcinoma (OPSCC) and the prognostic significance of patient, tumor, and treatment characteristics.

Methods: We retrospectively reviewed the data of patients treated at our Cancer Center for a p16-positive N3 OPSCC between 2003 and 2016. End points were overall survival (OS) and progression-free survival (PFS). Read More

View Article and Full-Text PDF

Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial.

Lancet 2019 01 15;393(10166):40-50. Epub 2018 Nov 15.

Department of Radiation Oncology, Stanford University, Stanford, CA, USA.

Background: Patients with human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma have high survival when treated with radiotherapy plus cisplatin. Whether replacement of cisplatin with cetuximab-an antibody against the epidermal growth factor receptor-can preserve high survival and reduce treatment toxicity is unknown. We investigated whether cetuximab would maintain a high proportion of patient survival and reduce acute and late toxicity. Read More

View Article and Full-Text PDF
January 2019

Primary Penile Cancer: The Role of Adjuvant Radiation Therapy in the Management of Extranodal Extension in Lymph Nodes.

Eur Urol Focus 2019 Sep 14;5(5):737-741. Epub 2018 Oct 14.

Department of Genitourinary Oncology, Moffitt Cancer Center, Tampa, FL, USA.

Background: In head and neck cancer, the presence of extranodal extension (ENE) in lymph nodes (LNs) has been shown prospectively to require adding chemotherapy to postoperative radiation therapy (RT). Limited data exist regarding ENE in LNs from primary penile cancer (PeCa).

Objective: To determine the association of RT and ENE in PeCa. Read More

View Article and Full-Text PDF
September 2019

Hypoglossal Nerve Stimulation and Heart Rate Variability: Analysis of STAR Trial Responders.

Otolaryngol Head Neck Surg 2019 01 18;160(1):165-171. Epub 2018 Sep 18.

6 Department of Biomedical Informatics, Emory University, Atlanta, Georgia, USA.

Objective: Hypoglossal nerve stimulation represents a novel therapy for the treatment of moderate-severe obstructive sleep apnea; nonetheless, its cardiovascular effects are not known. We examine the effects of hypoglossal nerve stimulation on heart rate variability, a measure of autonomic function.

Study Design: Substudy of the STAR trial (Stimulation Therapy for Apnea Reduction): a multicenter prospective single-group cohort. Read More

View Article and Full-Text PDF
January 2019

PET and Neck Ultrasound for the Detection of Cervical Lymphadenopathy in Patients with Lung Cancer and Mediastinal Lymphadenopathy.

Respiration 2018 4;96(2):138-143. Epub 2018 Jul 4.

Interventional Respiratory Unit, Galway University Hospital, Galway, Ireland.

Background: Cervical lymph nodes are frequently involved in patients with lung cancer and indicate inoperability. Some guidelines recommend neck ultrasound (NUS) in patients with bulky mediastinal lymphadenopathy. Positron emission tomography (PET) is indicated for patients with potentially curable disease. Read More

View Article and Full-Text PDF
December 2018

Phase 2 trial of neoadjuvant chemotherapy and transoral endoscopic surgery with risk-adapted adjuvant therapy for squamous cell carcinoma of the head and neck.

Cancer 2018 07 9;124(14):2986-2992. Epub 2018 May 9.

Division of Head and Neck Surgery, Department of Otolaryngology, Lineberger Comprehensive Cancer Center at the University of North Carolina, Chapel Hill, North Carolina.

Background: The objective of this study was to demonstrate the feasibility and efficacy of induction chemotherapy, surgery, and pathology-guided adjuvant therapy to treat transorally resectable squamous head and neck cancer.

Methods: Patients had squamous head and neck cancer that was resectable by the transoral route and advanced-stage disease (American Joint Committee on Cancer stage III-IV, T3-T4 tumors, and/or positive lymph nodes). They received treatment with weekly carboplatin at an area under the curve of 2, plus paclitaxel 135 mg/m , and daily lapatinib 1000mg for 6 weeks followed by surgical resection. Read More

View Article and Full-Text PDF

Induction chemotherapy followed by concurrent chemoradiation versus concurrent chemoradiation alone in the definitive management of p16-positive oropharyngeal squamous cell carcinoma with low-neck or N3 disease.

Oral Oncol 2018 03 20;78:151-155. Epub 2018 Feb 20.

Southern California Permanente Medical Group, Department of Radiation Oncology, Los Angeles, CA, United States. Electronic address:

Objective: The addition of induction chemotherapy (ICT) to concurrent chemoradiation (CCRT) has been investigated as a method of improving outcomes among patients with locally advanced head and neck squamous cell carcinoma. Previous studies have consisted of heterogeneous populations with both p16-positive and p16-negative disease and varying extent of nodal disease burden. We evaluated the role of ICT in p16-positive oropharyngeal squamous cell carcinoma (OPSCC) at high-risk of distant failure. Read More

View Article and Full-Text PDF

Importance of lymph node ratio for locoregional recurrence of squamous cell carcinoma of the buccal mucosa.

Head Neck 2017 12 5;39(12):2488-2493. Epub 2017 Oct 5.

Department of Oral and Craniomaxillofacial Plastic Surgery, University of Cologne, Cologne, Germany.

Background: There is no published study on the influence of lymph node ratio on locoregional recurrence of squamous cell carcinoma (SCC) of the buccal mucosa. Therefore, we focused in our study on this specific anatomic subsite.

Methods: We conducted a retrospective chart review of 95 patients from 2003-2013 with treatment-naive SCC of the buccal mucosa. Read More

View Article and Full-Text PDF
December 2017

[Management of T3 supraglottic carcinoma: a retrospective study].

Zhonghua Zhong Liu Za Zhi 2017 Aug;39(8):613-617

Department of Head and Neck Surgery, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.

To discuss the strategy of therapeutic management of T3 supraglottic carcinoma. A retrospective analysis of 459 patients with T3 supraglottic carcinoma treated in our hospital was performed. We evaluated the results of different managements, including surgery alone, preoperative radiotherapy, postoperative radiotherapy and radiotherapy alone. Read More

View Article and Full-Text PDF

Clinical outcomes for patients presenting with N3 head and neck squamous cell carcinoma: Analysis of the National Cancer Database.

Head Neck 2017 11 24;39(11):2159-2170. Epub 2017 Jul 24.

Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.

Background: There is a paucity of data regarding head and neck squamous cell carcinomas (HNSCCs) and N3 nodal disease.

Methods: Retrospective analysis of patients with N3 HNSCC identified in the National Cancer Database (NCDB) was performed.

Results: We identified 4867 patients with N3 HNSCC treated with primary surgery or chemoradiotherapy (CRT). Read More

View Article and Full-Text PDF
November 2017

Prognostic factors for head and neck cancer of unknown primary including the impact of human papilloma virus infection.

J Otolaryngol Head Neck Surg 2017 Jun 10;46(1):45. Epub 2017 Jun 10.

Department of Otorhinolaryngology - Head and Neck Surgery, University of Gothenburg, Sahlgrenska University Hospital, Göteborg, Sweden.

Background: Head and neck cancer of unknown primary (HNCUP) is rare and prospective studies are lacking. The impact of different prognostic factors such as age and N stage is not completely known, the optimal treatment is not yet established, and the reported survival rates vary. In the last decade, human papilloma virus (HPV) has been identified as a common cause of and important prognostic factor in oropharyngeal cancer, and there is now growing interest in the importance of HPV for HNCUP. Read More

View Article and Full-Text PDF

PP2A deactivation is a common event in oral cancer and reactivation by FTY720 shows promising therapeutic potential.

J Cell Physiol 2018 Feb 12;233(2):1300-1311. Epub 2017 Jun 12.

Environment-Omics-Diseases Research Center, China Medical University Hospital, Taichung, Taiwan.

Protein phosphatase 2A (PP2A) is a tumor suppressor gene, that has been frequently deactivated in many types of cancer. However, its molecular and clinical relevance in oral squamous cell carcinoma (OSCC) remain unclear. Here we show that, PP2A deactivation is a common event in oral cancer cells and hyperphosphorylation in its tyrosine-307 (Y307) residue contributes to PP2A deactivation. Read More

View Article and Full-Text PDF
February 2018

PET-NECK: a multicentre randomised Phase III non-inferiority trial comparing a positron emission tomography-computerised tomography-guided watch-and-wait policy with planned neck dissection in the management of locally advanced (N2/N3) nodal metastases in patients with squamous cell head and neck cancer.

Health Technol Assess 2017 04;21(17):1-122

Warwick Clinical Trials Unit, University of Warwick, Coventry, UK.

Background: Planned neck dissection (ND) after radical chemoradiotherapy (CRT) for locally advanced nodal metastases in patients with head and neck squamous cell carcinoma (HNSCC) remains controversial. Thirty per cent of ND specimens show histological evidence of tumour. Consequently, a significant proportion of clinicians still practise planned ND. Read More

View Article and Full-Text PDF

Unknown primary head and neck squamous cell carcinoma in the era of fluorodeoxyglucose-positron emission tomography/CT and intensity-modulated radiotherapy.

Head Neck 2017 07 28;39(7):1382-1391. Epub 2017 Mar 28.

Department of Radiation Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.

Background: The diagnosis and treatment of head and neck carcinoma of unknown primary (CUP) have changed with the introduction of fluorodeoxyglucose-positron emission tomography (FDG-PET)/CT and intensity-modulated radiotherapy (IMRT), with potential implications for outcome.

Methods: We conducted a retrospective analysis of 80 patients with head and neck CUP who were PET-staged and treated with curative intention using IMRT between 2006 and 2016 in the Netherlands Cancer Institute. Patient, tumor, and treatment demographics were recorded and oncologic outcomes were analyzed. Read More

View Article and Full-Text PDF

Survival impact of induction chemotherapy in advanced head and neck cancer: A National Cancer Database analysis.

Head Neck 2017 06 16;39(6):1113-1121. Epub 2017 Mar 16.

Department of Radiation Oncology, University of Colorado School of Medicine, Aurora, Colorado.

Background: Adding induction chemotherapy to concurrent chemotherapy and radiotherapy (RT) has generally not improved the overall survival (OS) in randomized trials of patients with head and neck cancer. This failure may stem from inadequate power or inappropriate patient selection, prompting this National Cancer Data Base analysis.

Methods: 8031 patients with T4 or N2b to N3 disease undergoing RT and chemotherapy were divided into induction chemotherapy and concurrent chemotherapy cohorts. Read More

View Article and Full-Text PDF

Therapeutic Management of Pyriform Sinus Cancer.

Otolaryngol Head Neck Surg 2017 03 10;156(3):498-503. Epub 2017 Jan 10.

1 ENT and Head and Neck Surgery Department, University Hospital of Amiens, Amiens, France.

Objective To analyze the survival rate of a nonselected pyriform sinus cancer population. Study Design Case series with chart review. Setting University hospital. Read More

View Article and Full-Text PDF

Laryngeal cancer: United Kingdom National Multidisciplinary guidelines.

J Laryngol Otol 2016 May;130(S2):S75-S82

Department of ENT-Head and Neck Surgery,Derby Royal Hospitals NHS Foundation Trust,Derby,UK.

This is the official guideline endorsed by the specialty associations involved in the care of head and neck cancer patients in the UK. Significantly new data have been published on laryngeal cancer management since the last edition of the guidelines. This paper discusses the evidence base pertaining to the management of laryngeal cancer and provides updated recommendations on management for this group of patients receiving cancer care. Read More

View Article and Full-Text PDF

Reevaluation of postoperative radiation dose in the management of human papillomavirus-positive oropharyngeal cancer.

Head Neck 2016 11 6;38(11):1643-1649. Epub 2016 May 6.

Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri.

Background: The purpose of this study was to compare outcomes of patients with p16-positive oropharyngeal squamous cell carcinoma (SCC) treated with postoperative intensity-modulated radiotherapy (IMRT) before and after an institutional dose reduction policy effective on February 2009.

Methods: Between 1998 and 2013, 175 consecutive patients with p16-positive oropharyngeal SCC with extracapsular extension (ECE) and/or close or positive margins were treated postoperatively to 66 Gy (n = 109) or 60 Gy (n = 66) in 2 Gy/fx.

Results: Between the 66 and 60 Gy groups, there was no difference in tumor classification (pT4 vs pT1-T3; p = . Read More

View Article and Full-Text PDF
November 2016

Increasing use of nonsurgical therapy in advanced-stage oral cavity cancer: A population-based study.

Head Neck 2017 01 19;39(1):82-91. Epub 2016 Sep 19.

Otolaryngology Head and Neck Surgery, The University of Utah School of Medicine, Salt Lake City, Utah.

Background: National guidelines support surgical-based treatment and offer nonsurgical therapy as an alternative for advanced-stage oral cavity squamous cell carcinoma (SCC). There are limited data evaluating current utilization of these therapies and their survival outcomes.

Methods: A total of 5856 patients were found in the Surveillance, Epidemiology, and End Results (SEER) database from 1988 to 2008 with resectable advanced-stage oral cavity SCC tumors. Read More

View Article and Full-Text PDF
January 2017

Oncologic outcomes of selective neck dissection in HPV-related oropharyngeal squamous cell carcinoma.

Laryngoscope 2017 03 16;127(3):623-630. Epub 2016 Sep 16.

Head and Neck Surgery Center of Florida, Celebration Hospital, Celebration, Florida, U.S.A.

Objectives: To examine outcomes of selective neck dissection (SND) in patients with human papillomavirus (HPV)-related oropharyngeal squamous cell carcinoma (OPSCC) who present with clinical neck disease.

Study Design: Multi-institutional retrospective review.

Methods: Two institutional databases of patients with HPV-related OPSCC were reviewed to identify patients with clinical (c) N1-N3 neck disease who underwent SND ± adjuvant therapy. Read More

View Article and Full-Text PDF